Core Viewpoint - The launch of Pemafibrate (brand name: Pailongda®) by Xinge Corporation on Alibaba Health marks the first official online availability of this selective PPARα modulator in China, providing a new treatment option for patients with hypertriglyceridemia (HTG) since its approval by the National Medical Products Administration in April 2025 [1][6]. Group 1: Product Overview - Pemafibrate is a next-generation selective PPARα modulator that has been available in Japan for nine years and is now being introduced to the Chinese market [1][6]. - The drug offers a combination of effective lipid-lowering properties and safety for liver and kidney functions, ensuring patients can purchase and use it with confidence [1][6]. Group 2: Clinical Significance - Hypertriglyceridemia is a common lipid disorder in China, with a prevalence rate of 15% to 22.4%, yet the treatment and control rates for affected patients are only 11.6% and 5.4%, respectively [5]. - The risk of microvascular events increases by 35% for every 1 mmol/L increase in triglyceride (TG) levels, and the risk of type 2 diabetes rises by 81% [5]. - Pemafibrate demonstrates a significant clinical advantage, with a molecular structure that activates PPARα over 2500 times more effectively than traditional fibrates [5]. Group 3: Efficacy and Guidelines - In clinical trials, a daily dose of 0.4 mg of Pemafibrate resulted in a triglyceride reduction of 51.8%, outperforming commonly used medications like fenofibrate [5]. - The drug is recognized in various authoritative guidelines, including the "Chinese Lipid Management Guidelines (2023)" and the European Society of Cardiology guidelines, confirming its regulatory compliance and efficacy [6]. Group 4: Target Population - Pemafibrate is suitable for adult patients with non-familial hypertriglyceridemia, particularly those with poor dietary control, diabetes, or fatty liver, and can be used alone or in combination with statins [6].

Core Viewpoint - Elevated triglyceride levels are an independent risk factor for myocardial infarction and are associated with increased risks of ischemic cardiovascular diseases and mortality, as highlighted by a large-scale study involving over 60,000 participants [1][5]. Group 1: Health Risks of Elevated Triglycerides - Triglycerides, a type of fat in the blood, can lead to the accumulation of "bad fat particles" that narrow and harden blood vessels, increasing the risk of ischemic cardiovascular events [5]. - High triglyceride levels can promote atherosclerosis, raising the risk of heart attacks and strokes, even when low-density lipoprotein (LDL) cholesterol levels are normal [5]. - The 2023 Chinese Blood Lipid Management Guidelines define elevated triglycerides as fasting levels of 1.7 mmol/L and above, with levels of 2.3 mmol/L and above classified as hypertriglyceridemia [6]. Group 2: Specific Health Concerns - Elevated triglycerides are linked to increased mortality risk from ischemic strokes in men, even within normal ranges, indicating a need to reassess safety thresholds [7]. - High triglycerides can lead to various health issues, including obesity, insulin resistance, acute pancreatitis, non-alcoholic fatty liver disease, and impaired kidney function [8][9][10]. Group 3: Monitoring and Management - Certain populations, such as those with a history of cardiovascular disease, multiple risk factors, or family history of early cardiovascular disease, should closely monitor triglyceride levels [11]. - The management of high triglycerides primarily involves dietary adjustments and weight loss, with recommendations for regular monitoring based on age and risk factors [13][17].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不對因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 蘇州瑞博生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） Suzhou Ribo Life Science Co., Ltd. （股份代號：6938） 自願公告 RBD5044於中國的II期臨床試驗默示許可 本公告由蘇州瑞博生物技術股份有限公司（「本公司」，連同其子公司統稱「本集 團」）自願作出，旨在向本公司股東（「股東」）及潛在投資者提供本集團研發進展的 最新情況。 本公司董事（「董事」）會（「董事會」）欣然宣佈，本集團自主研發的RBD5044注射 液已獲中國國家藥品監督管理局的II期臨床試驗默示許可。 香港，2026年1月23日 截至本公告日期，執行董事為梁子才博士、甘黎明博士及張鴻雁博士，非執行董 事為戚飛博士、李東方先生及李宇輝先生，及獨立非執行董事為宇學峰博士、馬 朝松先生及王瑞平先生。 RBD5044是一款靶向APOC3的siRNA藥物。APOC3是一種幾乎只在肝臟中合成 的蛋 ...